|
 Cheplapharm will pay AstraZeneca about $243 million for Losec, a
proton pump inhibitor developed by the British drugmaker. The sale
also includes milestone payments of up to $33 million in 2021 and
2022 contingent on sales.
The global commercial rights being sold to Cheplapharm, for Losec (omeprazole)
and its associated brands, excludes rights in China, Japan, the
United States and Mexico, AstraZeneca said.
AstraZeneca said it will still make and supply Losec and its
associated medicines and sell the medicine in markets where it still
holds the rights.
[to top of second column] |
In 2018, Losec sales in the countries covered under this agreement
with Cheplapharm were $98 million, the British drugmaker said.
The divestment includes medicines containing omeprazole marketed by
AstraZeneca or its collaborators sold under brands such as Acimax,
Antra, Mepral, Mopral, Omepral and Zoltum.
(Reporting by Muvija M and Aakash Jagadeesh Babu in Bengaluru;
Editing by Bernard Orr)
[© 2019 Thomson Reuters. All rights
reserved.] Copyright 2019 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |
